SG10201912964PA - Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease - Google Patents
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's diseaseInfo
- Publication number
- SG10201912964PA SG10201912964PA SG10201912964PA SG10201912964PA SG10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA
- Authority
- SG
- Singapore
- Prior art keywords
- tau
- alzheimer
- diagnosis
- protein
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161536339P | 2011-09-19 | 2011-09-19 | |
US201261653115P | 2012-05-30 | 2012-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912964PA true SG10201912964PA (en) | 2020-02-27 |
Family
ID=47216372
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703771WA SG10201703771WA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
SG10201912964PA SG10201912964PA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
SG10201912955PA SG10201912955PA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
SG11201400125RA SG11201400125RA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703771WA SG10201703771WA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912955PA SG10201912955PA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
SG11201400125RA SG11201400125RA (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
Country Status (30)
Country | Link |
---|---|
US (5) | US9518101B2 (hr) |
EP (2) | EP3275461A1 (hr) |
JP (7) | JP6253583B2 (hr) |
KR (3) | KR102285743B1 (hr) |
CN (3) | CN115417916A (hr) |
AU (3) | AU2012311234B2 (hr) |
BR (1) | BR112014006376B1 (hr) |
CA (1) | CA2848346A1 (hr) |
CL (3) | CL2014000679A1 (hr) |
CY (1) | CY1119792T1 (hr) |
DK (1) | DK2758433T3 (hr) |
ES (1) | ES2656442T3 (hr) |
HK (1) | HK1199459A1 (hr) |
HR (1) | HRP20180083T8 (hr) |
HU (1) | HUE036177T2 (hr) |
IL (4) | IL231201B (hr) |
LT (1) | LT2758433T (hr) |
ME (1) | ME03008B (hr) |
MX (1) | MX347505B (hr) |
MY (1) | MY183989A (hr) |
PL (1) | PL2758433T3 (hr) |
PT (1) | PT2758433T (hr) |
RS (1) | RS56852B1 (hr) |
RU (2) | RU2645259C2 (hr) |
SG (4) | SG10201703771WA (hr) |
SI (1) | SI2758433T1 (hr) |
TR (1) | TR201800669T4 (hr) |
UA (2) | UA115657C2 (hr) |
WO (1) | WO2013041962A1 (hr) |
ZA (1) | ZA201401333B (hr) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
MY171473A (en) | 2012-07-03 | 2019-10-15 | Univ Washington | Antibodies to tau |
CA2882034C (en) | 2012-08-16 | 2019-10-29 | Ipierian, Inc. | Methods of treating a tauopathy |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
MX2016006356A (es) * | 2013-11-27 | 2016-10-28 | Ipierian Inc | Metodos de tratamiento de una tauopatia. |
JP6654899B2 (ja) * | 2013-12-26 | 2020-02-26 | 東亞合成株式会社 | カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド |
WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
BR112016030183A2 (pt) * | 2014-06-26 | 2017-11-14 | Janssen Vaccines & Prevention Bv | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
JP6679582B2 (ja) | 2014-09-30 | 2020-04-15 | ワシントン・ユニバーシティWashington University | タウの動態測定 |
RU2020126237A (ru) * | 2014-11-19 | 2020-12-01 | Аксон Ньюросайенс Се | Гуманизированные тау-антитела при болезни альцгеймера |
JO3576B1 (ar) * | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
MA44955A (fr) | 2015-06-05 | 2019-03-20 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
AU2016289755C1 (en) | 2015-07-06 | 2021-08-19 | UCB Biopharma SRL | Tau-binding antibodies |
EP3319984A1 (en) | 2015-07-06 | 2018-05-16 | UCB Biopharma SPRL | Tau-binding antibodies |
JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
GB201518675D0 (en) * | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
CA3022515A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
CU24538B1 (es) | 2016-05-02 | 2021-08-06 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 |
BR112018073384A2 (pt) | 2016-05-18 | 2019-03-06 | Voyager Therapeutics, Inc. | polinucleotídeos moduladores |
KR101997319B1 (ko) | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용 |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2018117647A1 (ko) * | 2016-12-21 | 2018-06-28 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
KR20190133191A (ko) * | 2017-03-28 | 2019-12-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 타우에 특이적으로 결합하는 결합 분자 |
WO2018195376A1 (en) * | 2017-04-21 | 2018-10-25 | Ohio University | Peptide-based inhibitors of mark family proteins |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
JP7029718B2 (ja) * | 2017-07-31 | 2022-03-04 | 国立研究開発法人量子科学技術研究開発機構 | リン酸化タウタンパク質の測定方法 |
WO2019070721A1 (en) | 2017-10-02 | 2019-04-11 | Blackthorn Therapeutics, Inc. | METHODS AND TOOLS FOR DETECTING, DIAGNOSING, PREDICTING, PROGNOSING OR TREATING NEUROCOMPORTEMENTAL PHENOTYPE IN A SUBJECT |
JOP20200074A1 (ar) * | 2017-10-16 | 2020-04-30 | Eisai R&D Man Co Ltd | أجسام مضادة ضد tau واستخداماتها |
US11124552B2 (en) | 2017-10-25 | 2021-09-21 | Ac Immune Sa | Compositions of phosphorylated tau peptides and uses thereof |
WO2019120527A1 (en) * | 2017-12-20 | 2019-06-27 | Michael Heneka | Novel means and methods for treating neurodegenerative diseases |
CA3090356A1 (en) | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
WO2019186276A2 (en) * | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
RU2679059C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
RU2679080C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
MX2020011458A (es) * | 2018-05-03 | 2020-12-07 | Washington University St Louis | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. |
CR20210179A (es) | 2018-07-03 | 2022-05-23 | Hoffmann La Roche | OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058) |
CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
PE20211777A1 (es) * | 2018-11-08 | 2021-09-08 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
WO2020106598A1 (en) * | 2018-11-19 | 2020-05-28 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
WO2020193520A1 (en) * | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
AU2020283534B2 (en) * | 2019-05-31 | 2024-05-16 | Eli Lilly And Company | Compounds and methods targeting human tau |
GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
CN114641490B (zh) * | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | 结合至病理性tau种类的抗体及其用途 |
KR20220062287A (ko) * | 2019-08-13 | 2022-05-16 | 워싱턴 유니버시티 | Mtbr 타우 아이소폼 검출 방법 및 이의 용도 |
CN114531877A (zh) * | 2019-08-15 | 2022-05-24 | 学校法人东京医科大学 | 不受clsp阻碍物质影响的clsp衍生物和clsp活性的增强/保护剂 |
JP2022547513A (ja) | 2019-09-09 | 2022-11-14 | アクソン ニューロサイエンス エスエー | アルツハイマー病及び軽度認知障害のバイオマーカー及び治療 |
IL270800A (en) * | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
CN110841059A (zh) * | 2019-12-03 | 2020-02-28 | 南通大学 | 老年性痴呆小鼠模型的制备方法 |
TW202136297A (zh) * | 2020-02-05 | 2021-10-01 | 日商大日本住友製藥股份有限公司 | Tau蛋白病變及失智症相關疾病之判定藥及判定方法 |
WO2022115705A2 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
CN117136073A (zh) * | 2021-02-14 | 2023-11-28 | 普罗塞纳生物科学有限公司 | 使用识别tau的抗体的方法 |
CN116635414A (zh) * | 2021-02-19 | 2023-08-22 | 卫材R&D管理有限公司 | 抗pt217 tau抗体 |
CN113430230A (zh) * | 2021-06-24 | 2021-09-24 | 南通大学 | tau截断体蛋白在诱导tau病理聚集中的应用 |
WO2023060276A1 (en) * | 2021-10-08 | 2023-04-13 | Arbele Limited | Compositions and methods for detecting cadherin-17 protein |
CN113861441A (zh) * | 2021-10-28 | 2021-12-31 | 南开大学 | 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用 |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
CN116554342A (zh) * | 2022-01-29 | 2023-08-08 | 元本(珠海横琴)生物科技有限公司 | 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株 |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
CN117624354A (zh) * | 2023-11-30 | 2024-03-01 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau281兔单克隆抗体及其应用 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
DE69032483T2 (de) | 1989-10-05 | 1998-11-26 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
EP2009104A1 (en) * | 1991-12-06 | 2008-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
CA2169635C (en) | 1993-08-26 | 2002-11-12 | Dennis A. Carson | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
EP0791067B1 (en) * | 1994-10-28 | 2008-12-17 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Protein kinase npk-110 |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5643207A (en) | 1995-04-28 | 1997-07-01 | Medtronic, Inc. | Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
WO1997017614A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
US6198966B1 (en) | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
JP3383618B2 (ja) | 1999-08-18 | 2003-03-04 | 松下電器産業株式会社 | 移動体通信端末装置及び受信強度検出方法 |
AU7263600A (en) * | 1999-09-09 | 2001-04-10 | Mcgill University | Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases |
ATE326700T1 (de) | 1999-09-09 | 2006-06-15 | Max Planck Gesellschaft | SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß |
US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
ES2276732T3 (es) | 2001-09-03 | 2007-07-01 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Mimotopos de antigenos y vacuna contra enfermedades cancerosas. |
TWI226905B (en) | 2001-10-19 | 2005-01-21 | Bioware Technology Co Ltd | Low pressure-accelerated particle gene gun |
DK1521831T3 (da) | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgent dyr der udtrykker trunkeret alzheimers tauprotein |
EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
EP1516930A1 (en) | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
KR20070007253A (ko) | 2003-10-08 | 2007-01-15 | 이바이오사이언스 | 천연 면역글로불린 결합 물질 및 이의 제조 방법 및 사용방법 |
CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
WO2008084483A1 (en) * | 2007-01-11 | 2008-07-17 | Ramot At Tel Aviv University Ltd. | Novel therapeutics based on tau/microtubule dynamics |
TR201802286T4 (tr) * | 2007-04-20 | 2018-03-21 | The Chemo Sero Therapeutic Res Institute | Peptidle bağışıklık yanıtının arttırılması için yöntem. |
EP2171089B1 (en) * | 2007-06-25 | 2014-01-22 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EA032675B1 (ru) | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
US8778343B2 (en) | 2009-08-28 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
DK2496594T3 (en) * | 2009-11-06 | 2018-03-05 | The J David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS |
CN102858962A (zh) * | 2009-11-19 | 2013-01-02 | 索利斯拜欧代因公司 | 用于增加多肽稳定性和活性的组合物及相关方法 |
CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
-
2012
- 2012-09-14 AU AU2012311234A patent/AU2012311234B2/en active Active
- 2012-09-14 US US14/345,561 patent/US9518101B2/en active Active
- 2012-09-14 ME MEP-2018-18A patent/ME03008B/me unknown
- 2012-09-14 KR KR1020207018712A patent/KR102285743B1/ko active IP Right Grant
- 2012-09-14 PL PL12788639T patent/PL2758433T3/pl unknown
- 2012-09-14 KR KR1020147010525A patent/KR102130439B1/ko active IP Right Grant
- 2012-09-14 SG SG10201703771WA patent/SG10201703771WA/en unknown
- 2012-09-14 CN CN202210373330.XA patent/CN115417916A/zh active Pending
- 2012-09-14 CN CN201280056856.XA patent/CN104185640B/zh active Active
- 2012-09-14 EP EP17190247.1A patent/EP3275461A1/en active Pending
- 2012-09-14 SG SG10201912964PA patent/SG10201912964PA/en unknown
- 2012-09-14 BR BR112014006376-1A patent/BR112014006376B1/pt active IP Right Grant
- 2012-09-14 LT LTEP12788639.8T patent/LT2758433T/lt unknown
- 2012-09-14 SG SG10201912955PA patent/SG10201912955PA/en unknown
- 2012-09-14 CN CN201810662577.7A patent/CN109265543B/zh active Active
- 2012-09-14 HU HUE12788639A patent/HUE036177T2/hu unknown
- 2012-09-14 DK DK12788639.8T patent/DK2758433T3/en active
- 2012-09-14 PT PT127886398T patent/PT2758433T/pt unknown
- 2012-09-14 SI SI201231187T patent/SI2758433T1/en unknown
- 2012-09-14 SG SG11201400125RA patent/SG11201400125RA/en unknown
- 2012-09-14 RS RS20180054A patent/RS56852B1/sr unknown
- 2012-09-14 RU RU2014115481A patent/RU2645259C2/ru active
- 2012-09-14 TR TR2018/00669T patent/TR201800669T4/tr unknown
- 2012-09-14 CA CA2848346A patent/CA2848346A1/en not_active Abandoned
- 2012-09-14 EP EP12788639.8A patent/EP2758433B1/en active Active
- 2012-09-14 RU RU2018102103A patent/RU2018102103A/ru unknown
- 2012-09-14 UA UAA201404170A patent/UA115657C2/uk unknown
- 2012-09-14 JP JP2014530333A patent/JP6253583B2/ja active Active
- 2012-09-14 WO PCT/IB2012/002246 patent/WO2013041962A1/en active Application Filing
- 2012-09-14 UA UAA201706478A patent/UA123390C2/uk unknown
- 2012-09-14 MX MX2014003357A patent/MX347505B/es active IP Right Grant
- 2012-09-14 ES ES12788639.8T patent/ES2656442T3/es active Active
- 2012-09-14 MY MYPI2014000803A patent/MY183989A/en unknown
- 2012-09-14 KR KR1020217024024A patent/KR20210099167A/ko not_active Application Discontinuation
-
2014
- 2014-02-21 ZA ZA2014/01333A patent/ZA201401333B/en unknown
- 2014-02-27 IL IL231201A patent/IL231201B/en active IP Right Grant
- 2014-03-19 CL CL2014000679A patent/CL2014000679A1/es unknown
- 2014-12-24 HK HK14112922.2A patent/HK1199459A1/xx unknown
-
2015
- 2015-05-14 CL CL2015001314A patent/CL2015001314A1/es unknown
-
2016
- 2016-01-27 CL CL2016000215A patent/CL2016000215A1/es unknown
- 2016-11-03 US US15/342,629 patent/US9828421B2/en active Active
- 2016-11-28 JP JP2016230258A patent/JP6360869B2/ja active Active
-
2017
- 2017-02-24 JP JP2017033138A patent/JP6286590B2/ja active Active
- 2017-05-19 US US15/599,685 patent/US9845352B2/en active Active
- 2017-11-02 US US15/801,341 patent/US11098106B2/en active Active
- 2017-12-07 AU AU2017272259A patent/AU2017272259B2/en active Active
-
2018
- 2018-01-17 HR HRP20180083TT patent/HRP20180083T8/hr unknown
- 2018-01-17 CY CY20181100058T patent/CY1119792T1/el unknown
- 2018-03-27 JP JP2018059946A patent/JP6499345B2/ja active Active
- 2018-06-03 IL IL259775A patent/IL259775B/en active IP Right Grant
- 2018-07-12 JP JP2018132100A patent/JP6637124B2/ja active Active
-
2019
- 2019-12-19 JP JP2019228943A patent/JP6950981B2/ja active Active
-
2020
- 2020-01-29 AU AU2020200624A patent/AU2020200624B2/en active Active
- 2020-05-04 IL IL274440A patent/IL274440B/en unknown
-
2021
- 2021-07-27 US US17/443,779 patent/US20220010004A1/en active Pending
- 2021-09-15 JP JP2021150176A patent/JP7182316B2/ja active Active
- 2021-11-02 IL IL287794A patent/IL287794A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287794A (en) | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease | |
IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
EP2793993A4 (en) | RECOVERY AND PROCESSING OF HUMAN IN VIVO EMBRYOS | |
IL232256A0 (en) | Purine derivatives and their use in the treatment of diseases | |
EP2729148A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE | |
EP3628326C0 (en) | METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE | |
IL230957A0 (en) | Pharmacy methods and preparations for the treatment of an eye disease in a patient | |
GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
IL230441A0 (en) | Diagnosis of Alzheimer's disease | |
EP2568811A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
SG11201504447XA (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
IL237730B (en) | Treatment of mild and moderate Alzheimer's disease | |
EP2707486A4 (en) | DIAGNOSIS AND TREATMENT OF FRIEDREICH ATAXIA | |
PT2603238E (pt) | Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo | |
IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
GB201104720D0 (en) | Carncin - The use of L-carnosine and cinnamon in the treatment of alzheimer's disease | |
GB201113718D0 (en) | Treatment of Dupuytren's Disease |